Skip to main content
CDC Website

Considerations for the New Four-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB in the U.S.

Presented on September 21, 2021 by the TB Centers of Excellence and the Centers for Disease Control and Prevention

Audiences:
Health Professionals
Author:
Rutgers Global Tuberculosis Institute
Focus Area:
TB
Subjects:
TB Treatment
Publication Date:
2021
Format:
Webinar/Podcast
Links:
Last Updated Date:
Publication ID:
362336